ストックスクリーナーアプリを入手
28.34
4.73%
1.28
プレマーケット:
28.26
-0.08
-0.28%
前日終値:
$27.06
開ける：
$27.34
24時間の取引高:
695.68K
Relative Volume:
0.85
時価総額：
$1.62B
収益：
-
当期純損益:
$-100.44M
株価収益率:
-12.77
EPS:
-2.22
ネットキャッシュフロー:
$-105.32M
1週間 パフォーマンス:
+11.66%
1か月 パフォーマンス:
+1.58%
6か月 パフォーマンス:
-24.31%
1年 パフォーマンス:
-30.49%
1日の値動き範囲:
$26.86
$28.75
1週間の範囲:
$25.63
$28.75
52週間の値動き範囲:
$23.50
$62.74
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
名前
Structure Therapeutics Inc Adr
セクター
電話
(628) 229-9277
住所
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
GPCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
28.34 | 1.62B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-08 | 開始されました | Stifel | Buy |
| 2024-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-21 | 開始されました | JP Morgan | Overweight |
| 2024-04-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-07-27 | 開始されました | Piper Sandler | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | BMO Capital Markets | Outperform |
| 2023-02-28 | 開始されました | Guggenheim | Buy |
| 2023-02-28 | 開始されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | SVB Securities | Outperform |
すべてを表示
Structure Therapeutics Inc Adr (GPCR) 最新ニュース
Morningstar Mobile - Morningstar
Short Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Rises By 5.8% - MarketBeat
2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs - Morningstar
Novo’s Ozempic, Wegovy Targeted for Medicare Price Cuts - BNN Bloomberg
GAMMA Investing LLC Raises Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Schrödinger Secures $150M Novartis Deal, Advances Three Clinical Programs for 2025 - StockTitan
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - Defense World
Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year LowShould You Sell? - MarketBeat
Stifel Nicolaus Begins Coverage on Structure Therapeutics (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpHere's What Happened - MarketBeat
Stifel analysts initiate Structure Therapeutics stock with buy rating By Investing.com - Investing.com Canada
State Street Corp Increases Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Structure Therapeutics (NASDAQ:GPCR) Reaches New 1-Year LowShould You Sell? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 5.5%Here's Why - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Trading 5.6% HigherStill a Buy? - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Purchased by Principal Financial Group Inc. - MarketBeat
Barclays PLC Boosts Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Time to Buy? - Defense World
Structure Therapeutics (NASDAQ:GPCR) Shares Up 6.6%Still a Buy? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Earns "Buy" Rating from HC Wainwright - MarketBeat
Franklin Resources Inc. Boosts Stake in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics' SWOT analysis: oral obesity drug stock shows promise amid fierce competition - Investing.com
Here's Why VKTX Stock Plummeted 18% on Wednesday - Yahoo Finance
Merck moves into obesity with deal for Hansoh’s GLP-1 pill - BioPharma Dive
Structure Therapeutics (NASDAQ:GPCR) Sets New 1-Year LowWhat's Next? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Earns Market Outperform Rating from JMP Securities - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update - Defense World
Structure Therapeutics Selects Lead Oral Small Molecule for Obesity Treatment - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.67 Consensus PT from Brokerages - Defense World
Structure Therapeutics Advances Obesity Treatment Candidate - TipRanks
Structure Therapeutics Unveils Breakthrough Oral Obesity Drug, First-in-Class Amylin Agonist Shows Promise - StockTitan
Mcewen Mining Inc (MUX-N) QuotePress Release - The Globe and Mail
Structure Therapeutics' SWOT analysis: oral GLP-1 stock faces fierce competition - Investing.com
Market Factors: The biggest debatesand risksfor investors looking to outperform in 2025 - The Globe and Mail
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.67 Average PT from Analysts - MarketBeat
Exome Asset Management LLC Makes New $5.27 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc (GPCR-Q) QuotePress Release - The Globe and Mail
2 ‘Monster’ Stocks To Snap Up Before 2025 - Barchart
Y Intercept Hong Kong Ltd Makes New $1.79 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Pier Capital LLC Buys 33,087 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Wellington Management Group LLP Purchases 221,851 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Here’s Why - Defense World
FY2024 Earnings Estimate for GPCR Issued By Leerink Partnrs - Defense World
Brokers Offer Predictions for GPCR FY2024 Earnings - MarketBeat
Leerink Partnrs Has Bearish Outlook for GPCR FY2025 Earnings - Defense World
Bank of Montreal Can Has $1.94 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics' SWOT analysis: oral GLP-1 stock shows promise amid fierce competition By Investing.com - Investing.com South Africa
84,000 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Readystate Asset Management LP - MarketBeat
Point72 Asset Management L.P. Purchases 820,589 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc Adr (GPCR) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):